TGFβ2 Induces the Soluble Isoform of CTLA-4 – Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TGFβ2 Induces the Soluble Isoform of CTLA-4 – Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-01-05
DOI
10.3389/fimmu.2021.763877
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Transforming Growth Factor-β Signaling in Immunity and Cancer
- (2019) Eduard Batlle et al. IMMUNITY
- RGMB enhances the suppressive activity of the monomeric secreted form of CTLA-4
- (2019) Takashi Sekiya et al. Scientific Reports
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Contextual determinants of TGFβ action in development, immunity and cancer
- (2018) Charles J. David et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study
- (2018) Maria Pia Pistillo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor
- (2016) Silvio Roncella et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- TGF-β Tumor Suppression through a Lethal EMT
- (2016) Charles J. David et al. CELL
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
- (2016) Christophe Massard et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- Mutational signatures associated with tobacco smoking in human cancer
- (2016) L. B. Alexandrov et al. SCIENCE
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Molecular mechanisms of epithelial–mesenchymal transition
- (2014) Samy Lamouille et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
- (2014) S. Iwama et al. Science Translational Medicine
- Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels
- (2014) Anna M. Leung et al. Frontiers in Oncology
- The soluble isoform of CTLA-4 as a regulator of T-cell responses
- (2013) Frank J. Ward et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production
- (2013) Stefania Laurent et al. Journal of Translational Medicine
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Regulation of EMT by TGFβ in cancer
- (2012) Carl-Henrik Heldin et al. FEBS LETTERS
- A Soluble Form of CTLA-4 Is Present in Paediatric Patients with Acute Lymphoblastic Leukaemia and Correlates with CD1d+ Expression
- (2012) Rita Simone et al. PLoS One
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- TGFβ in Cancer
- (2008) Joan Massagué CELL
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started